diphenhydramine has been researched along with Neutropenia in 7 studies
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.
antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Paclitaxel was administered by 1 h intravenous infusion at a dose of 80 mg/m2 every week." | 6.71 | Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). ( Inoue, K; Kai, T; Koh, J; Mihara, H; Mochizuki, H; Okubo, K; Saito, T; Sato, K; Tabei, T, 2003) |
| "Temsirolimus (CCI-779) is a novel inhibitor of the mammalian target of rapamycin." | 2.75 | A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. ( Fujisaka, Y; Horiike, A; Tamura, T; Yamada, Y; Yamamoto, N, 2010) |
| "Paclitaxel was administered by 1 h intravenous infusion at a dose of 80 mg/m2 every week." | 2.71 | Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). ( Inoue, K; Kai, T; Koh, J; Mihara, H; Mochizuki, H; Okubo, K; Saito, T; Sato, K; Tabei, T, 2003) |
| "paclitaxel in the management of ovarian cancer appears justified." | 2.67 | Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer. ( Barakat, R; Curtin, J; Francis, P; Hakes, T; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rowinsky, E; Rubin, S, 1994) |
| " One patient experienced a life-threatening adverse reaction within minutes of receiving the first dose." | 1.31 | Pegylated liposomal doxorubicin: tolerability and toxicity. ( Goram, AL; Richmond, PL, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Charbonneau, K | 1 |
| Landry, P | 1 |
| Fujisaka, Y | 1 |
| Yamada, Y | 1 |
| Yamamoto, N | 1 |
| Horiike, A | 1 |
| Tamura, T | 1 |
| Sato, K | 1 |
| Inoue, K | 1 |
| Saito, T | 1 |
| Kai, T | 1 |
| Mihara, H | 1 |
| Okubo, K | 1 |
| Koh, J | 1 |
| Mochizuki, H | 1 |
| Tabei, T | 1 |
| Markman, M | 1 |
| Francis, P | 1 |
| Rowinsky, E | 1 |
| Hakes, T | 1 |
| Reichman, B | 1 |
| Jones, W | 1 |
| Lewis, JL | 1 |
| Rubin, S | 1 |
| Curtin, J | 1 |
| Barakat, R | 1 |
| Shepherd, FA | 1 |
| Latreille, J | 1 |
| Paul, K | 1 |
| Eisenhauer, E | 1 |
| Goram, AL | 1 |
| Richmond, PL | 1 |
| Wiernik, PH | 1 |
| Schwartz, EL | 1 |
| Einzig, A | 1 |
| Strauman, JJ | 1 |
| Lipton, RB | 1 |
| Dutcher, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study[NCT04829890] | 89 participants (Actual) | Observational | 2004-02-29 | Completed | |||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for diphenhydramine and Neutropenia
| Article | Year |
|---|---|
A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents; Area Under Curve; Carcinoma, Renal Cell; C | 2010 |
Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
Topics: Adult; Aged; Alopecia; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethaso | 2003 |
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer.
Topics: Dexamethasone; Diphenhydramine; Drug Administration Schedule; Female; Humans; Injections, Intraperit | 1994 |
Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1996 |
3 other studies available for diphenhydramine and Neutropenia
| Article | Year |
|---|---|
Leukopenia and neutropenia after intoxication with diphenhydramine (Nytol) during clozapine treatment.
Topics: Antipsychotic Agents; Clozapine; Diphenhydramine; Humans; Hypnotics and Sedatives; Leukopenia; Male; | 2008 |
Pegylated liposomal doxorubicin: tolerability and toxicity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diphenhydram | 2001 |
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Admin | 1987 |